Navigation Links
CryoLife Posts Record Annual Revenues of $116.6 Million
Date:2/17/2011

us from succeeding in the execution of our strategies.  Also, any expansion of product offerings may not be accepted by surgeons and patients, thereby preventing us from reaping the anticipated benefits of future investments.  Business development expenses may be more than anticipated.  Our ability to successfully distribute our remaining inventory of HemoStase may be impacted by the success of competitors in the market and our sales of PerClot.  We may ultimately sell significantly less than currently expected of our remaining HemoStase inventory.  Medafor may take action to attempt to prevent us from being able to continue to distribute HemoStase through late March 2011.  The date of our trial with Medafor will be set by the court and is beyond our control.  Estimated expenses in fiscal 2011 may be greater than those included in our fiscal 2011 guidance if we are successful in continuing to realize on our business development strategy and acquire additional complementary products or businesses, or if unexpected events, such as the need for further inventory write-downs, occur in fiscal 2011.  Our anticipated performance for the full year of fiscal 2011 is subject to the general risks associated with our business, including that we are significantly dependent on our revenues from BioGlue and are subject to a variety of risks affecting this product, including that a German Patent Court has nullified our main BioGlue patent in Germany, and if the ruling is upheld on appeal, we would be prevented from suing to prevent third parties from infringing the main BioGlue patent in Germany, we are subject to stringent domestic and foreign regulation which may impede the approval process of our tissues and products, hinder our development activities and manufacturing processes, and, in some cases, result in the recall or seizure of previously cleared or approved tissues and products, we expect HemoStase sales to cease in late Mar
'/>"/>

SOURCE CryoLife, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. CryoLife Announces Release Date and Teleconference Call Details for 2010 Fourth Quarter and Year End Financial Results
2. CryoLife to Present at Lazard Capital Markets 7th Annual Healthcare Conference
3. CryoLife Begins Distribution of Blood-Clotting Agent PerClot® in Europe
4. CryoLife Announces Release Date and Teleconference Call Details for 2010 Third Quarter Financial Results
5. CryoLife Receives Japanese Regulatory Approval for BioGlue Surgical Adhesive
6. CryoLife Enters into Worldwide Distribution and Manufacturing Agreements with Starch Medical for Novel Hemostatic Agent
7. CryoLife Provides Initial 2010 Financial Guidance
8. CryoLife to Present at 21st Annual Piper Jaffray Health Care Conference
9. CryoLife to Present at Upcoming Investor Conferences in New York
10. CryoLife Reports Record Quarterly Revenues of $28.2 Million
11. CryoLife Receives FDA Approval to Begin U.S. Clinical Trial for BioFoam(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 2015  Growth of the U.S. nonprescription market is ... prescription users to the OTC market. Due to an ... Rx-to-OTC switch activity over the next five years with ... new brands entering the market into existing categories. ... years (even those with low to moderate likelihood), the ...
(Date:7/30/2015)... 30, 2015  Medimetriks Pharmaceuticals, Inc. announced today ... III clinical study for Ozenoxacin, a novel bactericidal ... the exclusive U.S. rights to Ozenoxacin 1% cream.  ... 44 centers with an emphasis on U.S. patients, ... months and older with a clinical diagnosis of ...
(Date:7/30/2015)... 2015 Vermillion, Inc. (VRML), a ... announced today it will report its second ... close on Thursday, August 13, 2015, followed ... at 4:30pm Eastern.Conference Call and Webcast:  ... Pacific  Domestic: , 888-430-8691International: ...
Breaking Medicine Technology:Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 3Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3
(Date:7/30/2015)... ... July 30, 2015 , ... Eyepartner is proud ... in San Diego, California’s Gaslamp Quarter Plaza for five years this September. , ... monitor the area for any suspicious activity. These cameras are in place to ...
(Date:7/30/2015)... ... July 30, 2015 , ... " DevExpress ” ... a look at small, medium, and large businesses making an impact in their ... business review and shared with viewers how DevExpress has provided software development tools ...
(Date:7/30/2015)... ... July 30, 2015 , ... The Beryl ... Scholar Program. In partnership with Patient Experience Institute, these offerings reinforce the commitment ... the front lines and throughout the experience movement, and provide information and research ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... today that the latest issue of Inclusive™ magazine, its multimedia publication focused on ... digital edition of the new issue, Volume 6, Issue 2, as well as ...
(Date:7/30/2015)... ... July 30, 2015 , ... Between 2012 and 2014 HIV ... Health News Florida on June 17th. Those untreated heroin use disorders share their ... the spread of dirty needles throughout the community. Ultimately Florida’s HIV infection rates have ...
Breaking Medicine News(10 mins):Health News:Eyepartner Software Helps Victims in Gaslamp Quarter Plaza 2Health News:Eyepartner Software Helps Victims in Gaslamp Quarter Plaza 3Health News:Software to Develop High-Performance Data-Driven Apps was Featured on NewsWatch Television 2Health News:The Beryl Institute Opens Applications for 2015 Patient Experience Grant and Scholar Programs 2Health News:The Beryl Institute Opens Applications for 2015 Patient Experience Grant and Scholar Programs 3Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 2Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 3Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 4Health News:HIV Rates Rise in S. Florida, Harbor Village Comments on Health News Florida's Recent Article 2Health News:HIV Rates Rise in S. Florida, Harbor Village Comments on Health News Florida's Recent Article 3
... The naturally high levels of leptin in diabetic patients ... treat heart blockages, but using a chemical that differs ... counteract this effect. , The work by researchers at ... diabetics who get stents, they say. Though drug-eluting stents ...
... Pheromone,Sciences, Inc. (OTC Bulletin Board: EROX) ("HPS" or "the ... with the U.S. Patent and,Trademark Office for the use ... in sea coral, which has significant emotional impacts,on both ... well-being and social attraction. , ...
... United Health Foundation announced its commitment to American Indian ... Indian Country by donating $45,000 for nine $5,000 scholarships ... support of Arizona students pursuing careers in the health ... scholarship recipients were chosen based on their academic achievement, ...
... SACRAMENTO, Calif., Dec. 17 Sutter Health has announced,the ... general,counsel. She will assume her new role January 5, ... , Formerly senior ... Eisenbeis, LLP (HRDE) for the past two decades, DiBenedetto,served ...
... Hospital have answered a central question in cancer biology: ... Stem cells are immature cells that can renew themselves ... the range of body tissues. In recent years, researchers ... forms of stem cells. , Like a brand-name ...
... Combines ZEISS,s Precision Progressive Lenses and Transitions® Lenses to Produce Optimal ... ... 17, 2008 -- Two of the most distinguished names in the ... leading-edge eyewear., , ,Carl Zeiss Vision, a leader for 160 years ...
Cached Medicine News:Health News:HPS Files Patent for Mood-Enhancing Compound Naturally Found in Sea Coral 2Health News:United Health Foundation Provides $45,000 for Scholarships to the American Indian College Fund for Arizona Healthcare Students 2Health News:United Health Foundation Provides $45,000 for Scholarships to the American Indian College Fund for Arizona Healthcare Students 3Health News:Sutter Health Welcomes New General Counsel 2Health News:Molecular marker identifies normal stem cells as intestinal tumor source 2Health News:Carl Zeiss Vision and Transitions Optical Inc. Promote Pioneering Eyewear to Consumers 2
... up to 10 inches/ 25 cm thinner than other ... Allegra X-22 Series is the space-saving multipurpose solution for ... / 46 cm wide • 11 Rotor Library • ... ways to Spin 1.5 mL & PCR+ Tubes: ...
... is up to 10 inches/ 25 cm thinner than ... the Allegra X-22 Series is the space-saving multipurpose solution ... inches / 46 cm wide • 11 Rotor Library ... different ways to Spin 1.5 mL & PCR+ Tubes: ...
... centrifuges offer high-volume versatility along with a ... them ideal for a wide variety of ... Four- or six-place sealed swinging bucket rotor, ... offered , Lare capacity (4 x 750 ...
... Multipurpose high performance centrifuge designed to accommodate ... devices is refrigerated for heat labile samples. ... include refrigerated capability with automatic quick cooling ... < 7 min, no maintenance brushless motor, ...
Medicine Products: